Vancouver, British Columbia – November 15, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF) has released its financial and operating results for the three and nine months ended September 30, 2021, reporting significant advancement in its operations and strong liquidity.

"We continued to make significant strides forward in the third quarter and are well positioned to be the global leader in biosynthetically produced cannabinoids," said Trevor Peters, Willow's President and Chief Executive Officer. "From our vantage point, we can see the larger players in the consumer-packaged goods ecosystem becoming increasingly more bullish on the health and wellness aspects of the cannabis industry. It has been our view all along that these entities need an ultra-pure, sustainably sourced ingredient supply to meet their long-term demands, and Willow’s technology platform enables their entrance into this space.”

Highlights for the Quarter

• On July 20, 2021, Willow announced that it had added cannabinol (“CBN”) to its development program. Early research indicates that CBN may be effective as a sleep aid or sedative, in addition to other potential health benefits.

• On July 20, 2021, the Company announced the formation of a senior level Environmental, Social, and Governance ("ESG") committee to oversee sustainability integration efforts and to provide a direct line from operations to the board of directors on all ESG matters. ESG priorities for Willow in 2021 and 2022 include ESG strategy development, data management on identified safety, environmental, and social KPIs, target-setting, and internal and external stakeholder engagement.

• On September 21, 2021, Willow announced that it had increased its production titer by >400% and has carried out additional fermentation runs yielding tens of kilograms of ultra-pure CBG at >10,000 L fermentation scale, since its first commercial scale run in March of 2021.

• On September 21, 2021, Willow announced that it had developed a process for production of ultrapure cannabigerolic acid (“CBGA”). Samples are available for customer assessment and product development.

• During the quarter, Willow added fermentation capacity to its lab in Burnaby, British Columbia, and subsequent to the quarter, the Company’s wholly owned subsidiary, Willow Analytics, received a cannabis research license from Health Canada to operate in this expanded portion of its lab.

• Willow ended the quarter with strong liquidity, including approximately $35.7 million of cash on hand as at September 30, 2021.

Operational Update

In March 2021, Willow completed its first commercial scale fermentation run of cannabigerol (“CBG”) with its manufacturing partner at their European facilities. The product from this first run was primarily used for customer samples and to provide material to Cellular Goods PLC (“Cellular Goods”) as a part of their June 2021 supply agreement. Since this initial production run, Willow has increased its production titer by >400% and has carried out additional fermentation runs yielding tens of kilograms of ultra-pure CBG at >10,000 L fermentation scale. The Company continues to make significant titer improvements to its strain, with further production runs planned through the end of the year.

As stated previously, Willow has also engaged a regulatory consulting group to attain an Independent Generally Recognized as Safe ("GRAS") conclusion for Willow CBG that is required for use in food and beverage applications and continues this process which will be completed in 2022.

During the third quarter of 2021, the Company added resources and expertise to manage commercial production and further expand its R&D capabilities to grow its product portfolio. Willow has expanded its Burnaby, British Columbia and Mountain View, California teams to include manufacturing, quality and regulatory groups, along with additional R&D scientists focusing on strain optimization and process development. Willow also added fermentation capacity to its lab in Burnaby, British Columbia, and subsequent to the quarter, the Company’s wholly owned subsidiary, Willow Analytics, received a cannabis research license from Health Canada to operate in this expanded portion of its lab.

With Willow's lead proprietary yeast strain now producing biosynthetic CBG at commercial scale, and agreements in place to generate product revenue, Willow's R&D teams are now focused on development of cannabidiol (“CBD”) and tetrahydrocannabinol ("THC") programs for commercial manufacture. In addition to Willow's commercial development programs for CBG, CBD and THC, Willow's R&D team continues to develop biosynthetic processes for cannabidivarin ("CBDV"), cannabigerovarin ("CBGV"), and tetrahydrocannabivarin ("THCV"), and has added an additional development project for production of CBN from its biosynthetically derived CBD or THC. Early research indicates that CBN may be effective as a sleep aid or sedative, in addition to other potential health benefits. The Center of Disease Control's Sleep and Sleep Disorder Program states that one in three adults in the United States do not get enough sleep, a crucial component for good health, and CBN is increasingly being incorporated into consumer products designed to improve sleep quality.

Financial Update

Willow ended the quarter in a strong financial position, with approximately $35.7 million in cash on hand.

The Company's financial results are summarized as follows:

\ As at September 30

\ 2021 2020

Balance sheet ($000's):

Cash and cash equivalents 35,729 9,092

Total assets 41,043 16,049

Shareholder's equity 34,347 3,627

Weighted average shares outstanding:

Basic (000's) 123,545 78,892

Diluted (000's) 136,597 78,892


Willow completed its first commercial scale fermentation run of its first cannabinoid, CBG, in Q1 2021 and signed up its first multi year commercial agreement with Cellular Goods in Q2 2021. This agreement was a significant turning point in the lifecycle of the Company as it demonstrates that Willow has the full technical and business development capabilities to meet customer demands. During the remainder of 2021, Willow plans to continue to optimize its commercial process for CBG, supply product to customers, seed commercial samples to new potential customers, and build out a robust order book for 2022. CBG is a rare cannabinoid and Willow is at the forefront of developing that market.

The Company has two distinct objectives at this time. The first is to continue to work with larger groups to lock up supply agreements for its biosynthetically produced CBG. The second is to continue to advance the development of its portfolio of other cannabinoids to bring them forward to commercialization. While the timing of the first is harder to predict, the Company is currently engaged in very promising discussions with interested third parties and believes that its core technology will be significant in helping to enable the more traditional consumer-packaged goods entities enter the cannabinoid space.

With $35.7 million of cash on the Company's balance sheet as at September 30, 2021, favourable regulatory regime changes being discussed in the United States, a first commercial production run completed and first commercial agreement signed, the Company is in a position of strength to execute on its business plan. While the market for biosynthetically produced cannabinoids is new, Willow is at the forefront of this industry and will continue to demonstrate itself as a market leader.

A full description of Willow's third quarter 2020 results can be found in Willow's unaudited condensed consolidated interim financial statements and related management's discussion and analysis which are available on SEDAR at www.sedar.com.

About Willow Biosciences Inc.

Willow is a leading biotechnology company that develops and produces high-purity, plant derived ingredients for the consumer care, food and beverage, and pharmaceutical markets. Willow's biotechnology platform allows creation of a consistent, scalable and sustainable product that benefits both B2B and B2C customers. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products for both the consumer and pharmaceutical industries.

For further information, please visit our website at www.willowbio.com or contact:

Trevor Peters

President and Chief Executive Officer

Troy Talkkari, CFA

Vice President, Corporate Development

E: info@willowbio.com

150, 2250 Boundary Road

Burnaby, BC V5M 3Z3

Forward-Looking Statements

This news release may include forward-looking statements including opinions, assumptions, estimates and the Company's assessment of future plans and operations, and, more particularly, statements concerning: Willow's milestone projections, including the timing of CBG production and revenue generation and commercial manufacturing of CBD and THC; the progress of Willow's commercial development programs for CBD, THC, CBDV, CBGV, THCV and CBN; the results of negotiations with strategic partners and potential customers, including product orders resulting therefrom; the receipt of a GRAS conclusion in respect of Willow's CBG; the therapeutic benefits of CBN; global market forecasts for biosynthetically derived cannabinoids and Willow's ability to capture market share; Willow's ESG efforts and objectives; and the business plan of the Company, generally, including cannabinoid research and production. When used in this news release, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Company which include, but are not limited to: the success of Willow's strategic partnerships, including the development of future strategic partnerships; the financial strength of the Company; the ability of the Company to fund its business plan using cash on hand and existing resources; the market for Willow's products; the ability of the Company to obtain and retain applicable licences; the ability of the Company to obtain suitable manufacturing partners and other strategic relationships; and the successful implementation of Willow's commercialization and production strategy, generally. Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to, risks associated with: the cannabinoid industry in general; the success of the Company's research and development strategies; infringement on intellectual property; failure to benefit from partnerships or successfully integrate acquisitions; actions and initiatives of federal and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; import/export and research restrictions for cannabinoid-based operations; the size of the medical-use and adult-use cannabinoid market; competition from other industry participants; adverse U.S., Canadian and global economic conditions; adverse global events and public-health crises, including the current COVID-19 outbreak; failure to comply with certain regulations; departure of key management personnel or inability to attract and retain talent; and other factors more fully described from time to time in the reports and filings made by the Company with securities regulatory authorities. Please refer to the AIF and the MD&A for additional risk factors relating to Willow, which can be accessed either on Willow's website at www.willowbio.com or under the Company's profile on www.sedar.com.

The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.


Latest news, media & events